Evidence map›Paper›PMID 40419563›Full record

ArticleNPJ Parkinson's disease2025

T cell responses towards PINK1 and α-synuclein are elevated in prodromal Parkinson's disease.

Emil Johansson, Antoine Freuchet, Gregory P Williams, Tanner Michealis, April Frazier, Irene Litvan, Jennifer G Goldman, Roy N Alcalay, David G Standaert, Amy W Amara and 7 more

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Emil JohanssonCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Antoine FreuchetCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Gregory P WilliamsCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Tanner MichealisCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
April FrazierCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Irene LitvanDepartment of Neuroscience, University of California San Diego, La Jolla, CA, USA.
Jennifer G GoldmanJPG Enterprises LLC (prior: Shirley Ryan Ability Lab and Northwestern University Feinberg School of Medicine), Chicago, IL, USA.
Roy N AlcalayDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
David G StandaertDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Amy W AmaraDepartment of Neurology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Natividad StoverDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Edward A FonDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.
Ronald B PostumaThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, H3A 2B4, Canada.
John SidneyCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
David SulzerAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815, USA.
Cecilia S Lindestam ArlehamnCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. alex@lji.org.

Funding

Autoimmune Features of Neurodegenerative DisordersR01NS095435 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SETTE, ALESSANDRO, SULZER, DAVID · 2018 to 2022
$4.2M
Aligning Science Across Parkinson's ASAP-000375NINDS NIH HHS R01 NS095435NINDS NIH HHS R01NS095435Vetenskapsrådet 2024-00175
6 · The paper itself

Abstract

A role of the immune system in Parkinson's disease (PD) progression has long been suspected due to the increased frequency of activated glial cells and infiltrating T cells in the substantia nigra. It was previously reported that PD donors have increased T cell responses towards PINK1 and α-synuclein (α-syn), two Lewy body-associated proteins. Further, T cell reactivity towards α-syn was highest closer to disease onset, highlighting that autoreactive T cells might play a role in PD pathogenesis. However, whether T cell autoreactivity is present during prodromal PD is unknown. Here, we investigated T cell responses towards PINK1 and α-syn in donors at high risk of developing PD (i.e. prodromal PD: genetic risk, hyposmia, and or REM sleep behavior disorder), in comparison to PD and healthy control donors. T cell reactivity to these two autoantigens was detected in prodromal PD at levels comparable to those detected in individuals with clinically diagnosed PD. Aligned with the increased incidence of PD in males, we found that males with PD, but not females, had elevated T cell reactivity compared to healthy controls. However, among prodromal PD donors, males and females had elevated T cell responses. These differing trends in reactivity highlights the need for further studies of the impact of biological sex on neuroinflammation and PD progression.

Identifiers

PMID40419563
PMCPMC12106619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.